July 22, 2024 03:05 PM EDT
Pharma
FDA+
Law

Blue­bird bio hand­ed neg­a­tive opin­ion from fed­er­al over­sight agency for fer­til­i­ty sup­port pro­gram

Nicole DeFeudis

Editor

HHS’ Of­fice of the In­spec­tor Gen­er­al has is­sued a neg­a­tive ad­vi­so­ry opin­ion for a fer­til­i­ty sup­port pro­gram pro­posed by blue­bird bio, less than a week …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times